|
|
Blood, 15 October 2007, Vol. 110, No. 8, pp. 2793-2802.
Prepublished online as a Blood First Edition Paper on July 17, 2007; DOI 10.1182/blood-2007-02-072843.
 Previous Article | Table of Contents | Next Article 
PLENARY PAPER
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes
Concetta Quintarelli1,
Juan F. Vera1,
Barbara Savoldo1,
Greta M. P. Giordano Attianese1,
Martin Pule1,
Aaron E. Foster1,
Helen E. Heslop1,
Cliona M. Rooney1,
Malcolm K. Brenner1, and
Gianpietro Dotti1
1 Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX
The antitumor effect of adoptively transferred tumor-specific cytotoxic T lymphocytes (CTLs) is impaired by the limited capacity of these cells to expand within the tumor microenvironment. Administration of interleukin 2 (IL-2) has been used to overcome this limitation, but the systemic toxicity and the expansion of unwanted cells, including regulatory T cells, limit the clinical value of this strategy. To discover whether transgenic expression of lymphokines by the CTLs themselves might overcome these limitations, we evaluated the effects of transgenic expression of IL-2 and IL-15 in our model of Epstein Barr Virus–specific CTLs (EBV-CTLs). We found that transgenic expression of IL-2 or IL-15 increased the expansion of EBV-CTLs both in vitro and in vivo in a severe combined immunodeficiency disease (SCID) mouse model and enhanced antitumor activity. Although the proliferation of these cytokine genes transduced CTLs remained strictly antigen dependent, clinical application of this approach likely requires the inclusion of a suicide gene to deal with the potential development of T-cell mutants with autonomous growth. We found that the incorporation of an inducible caspase-9 suicide gene allowed efficient elimination of transgenic CTLs after exposure to a chemical inducer of dimerization, thereby increasing the safety and feasibility of the approach.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Warrior, miscreant, suicide: making better killers
- Mark E. Dudley
Blood 2007 110: 2781-2782.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
A. Di Stasi, B. De Angelis, C. M. Rooney, L. Zhang, A. Mahendravada, A. E. Foster, H. E. Heslop, M. K. Brenner, G. Dotti, and B. Savoldo
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model
Blood,
June 18, 2009;
113(25):
6392 - 6402.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. U. Louis, K. Straathof, C. M. Bollard, C. Gerken, M. H. Huls, M. V. Gresik, M.-F. Wu, H. L. Weiss, A. P. Gee, M. K. Brenner, et al.
Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients
Blood,
March 12, 2009;
113(11):
2442 - 2450.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Boni, P. Muranski, L. Cassard, C. Wrzesinski, C. M. Paulos, D. C. Palmer, L. Gattinoni, C. S. Hinrichs, C.-C. Chan, S. A. Rosenberg, et al.
Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers
Blood,
December 1, 2008;
112(12):
4746 - 4754.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. A. Rabinovich, Y. Ye, T. Etto, J. Q. Chen, H. I. Levitsky, W. W. Overwijk, L. J. N. Cooper, J. Gelovani, and P. Hwu
Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer
PNAS,
September 23, 2008;
105(38):
14342 - 14346.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Quintarelli, G. Dotti, B. De Angelis, V. Hoyos, M. Mims, L. Luciano, H. E. Heslop, C. M. Rooney, F. Pane, and B. Savoldo
Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia
Blood,
September 1, 2008;
112(5):
1876 - 1885.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
